P1190 - Intersecting Paths of Osteoarthritis and Metabolic-Associated Steatotic Liver Disease

Khalid Aloum, MD¹, Arnold N. Forlemu, MD, MPH², Wendy T. Garzon-Siatoya, MD¹, Amelia Panjwani, BSc³, Camelia Ciobanu, MD⁴, Amr Dokmak, MD⁴, Mohammed Abusuliman, MD⁵, Vikash Kumar, MD⁶, Praneeth Bandaru, MBBS, MD⁴, Raissa Nana Sede Mbakop, MD⁷, Manasa Ginjupalli, MD⁴, Vijay Reddy Gayam, MD⁸, Anuj R. Sharma, MBBS⁴, Denzil Etienne, MD⁴, Madhavi Reddy, MD, FACG⁴, Nithan Narendra, MD^1
1St. Barnabas Hospital, Bronx, NY; ²Brooklyn Hospital Center, Athens, GA; ³St. George's University School of Medicine, Brooklyn, NY; ⁴Brooklyn Hospital Center, Brooklyn, NY; ⁵Henry Ford Health, Detroit, MI; ⁶Creighton University School of Medicine, Brooklyn, NY; ⁷The Brooklyn Hospital Center, Brooklyn, NY; ⁸University of Texas Southwestern Medical Center, Dallas, TX

Introduction: Metabolic-associated steatotic liver disease (MASLD) is characterized by hepatic fat accumulation in individuals with metabolic risk factors such as obesity, insulin resistance, dyslipidemia, and hypertension. Osteoarthritis (OA) is the predominant form of arthritis and involves progressive joint cartilage degeneration. A recent national study reported a significant association between the two diseases.

MASLD and OA share metabolic etiologies. Whether both conditions are related still needs elucidating.

Methods: Patients with a diagnosis of OA and patients with a diagnosis of MASLD were identified utilizing the National Inpatient Sample (NIS) data from 2016 to 2020.

Primary outcome was the association of the two diseases in the general population tested by multivariable logistic regression analysis.

Secondary outcomes were the differences in the characteristics and outcomes between a cohort of MASLD with OA and a control cohort of MASLD without OA.

Unweighted data from NIS were multiplied with appropriate discharge and hospital-level weights to represent the population across the USA.

Results: .
OA was significantly associated with MASLD [OR=1.226; p=0.00; CI 1.21-1.24) with adjusting for sex, age, race, Charlson Comorbidity Index, obesity, smoking, location and hospital characteristics.



Out of a total of 2,982,525 with MASLD,10.78% of those patients had osteoarthritis.

Patients with MASLD that had OA were older in age than MASLD who didnt have OA (63 years vs 54 years), had higher percentage of females (64% vs 52%), had a higher component of white ethnicity (77% vs 66%) and had a higher percentage of Medicare insured patients (58% vs 38%).



Interestingly, MASLD with OA were noted to have a lower mortality rate, shorter length of stay, and fewer total charges. All the aforementioned results were statistically significant with a p< 0.0001.

The rest of the results of the comparison between the two cohorts are in the attached table.

Discussion: This study establishes a positive association between OA and MASLD. Shared risk factors such as obesity, dyslipidemia, and insulin resistance, alongside chronic low-grade inflammation, likely contribute to their co-occurrence through shared metabolic and inflammatory pathways. The findings in this study highlight the importance of understanding the relationship between OA and MASLD, and warrant further investigation into the causal pathways, therapeutic interventions, and comprehensive management approaches to improve outcomes for affected individuals.


Disclosures:


Khalid Aloum, MD¹, Arnold N. Forlemu, MD, MPH², Wendy T. Garzon-Siatoya, MD¹, Amelia Panjwani, BSc³, Camelia Ciobanu, MD⁴, Amr Dokmak, MD⁴, Mohammed Abusuliman, MD⁵, Vikash Kumar, MD⁶, Praneeth Bandaru, MBBS, MD⁴, Raissa Nana Sede Mbakop, MD⁷, Manasa Ginjupalli, MD⁴, Vijay Reddy Gayam, MD⁸, Anuj R. Sharma, MBBS⁴, Denzil Etienne, MD⁴, Madhavi Reddy, MD, FACG⁴, Nithan Narendra, MD¹. P1190 - Intersecting Paths of Osteoarthritis and Metabolic-Associated Steatotic Liver Disease, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.